ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Endocrine Society Releases New Version of their Testosterone Clinical Practice Guideline
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 101376" data-attributes="member: 3"><p>No earth-shattering changes except that now they mention estradiol in different tables but do not recommend estradiol testing.</p><p></p><p>[ATTACH]4807[/ATTACH]</p><p></p><p>"We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone&#8211;binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy."</p><p></p><p>Full paper can be downloaded by registered members. <a href="https://www.excelmale.com//register.php" target="_blank">Register here</a></p><p></p><p><a href="https://watermark.silverchair.com/jc.2018-00229.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAcIwggG-BgkqhkiG9w0BBwagggGvMIIBqwIBADCCAaQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMGSlmWlButqkZOjXCAgEQgIIBdQSZOtdqDb5r6OPayuvZTEPALno41vNVgyJpD-pQvRa9AzuBvZY8A0LYOrFS8dxRlf19GETJcFtXMDd8CYpzhQmiioxBmMoVtZHqgAhDoi8t8XVoP-u0CUQMgP1e6nF7CEP1unVf1lPAJHk7Fa6HoOLrL0DAxD6hV-luRftUNW57665jZgdQsVmwhdr4vep0LcgLkqn-Gvtl30uqJJMBQAdzA-TwqEqQUIIReyhQ0T0X3ELB-z_oFPGbyQr1maUK-csBkM4Ijjy0c7rUgvdnDWEkzn_XlBbb0wsd47YEUFATbj-CA2omltWfF5mgL4FpZw3_3lyIMNek5SgjEkxhSwYD04eDGMCTxJ3aYuPTTCO1dPox9UJ8nbX0nswpVhE3Z8Rg1YO6-ai6yvB_jeP_PA0sJT1mvUykUe7kvhyCe5VcNfqzZHIGNR-dBMHO2XcWC00TY9_D4rXrcOMyHg2csWdQERyHIJsXT7tiZUE_6TK_3RPH7U0" target="_blank">Click here</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 101376, member: 3"] No earth-shattering changes except that now they mention estradiol in different tables but do not recommend estradiol testing. [ATTACH=CONFIG]4807[/ATTACH] "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone–binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy." Full paper can be downloaded by registered members. [URL="https://www.excelmale.com//register.php"]Register here[/URL] [URL="https://watermark.silverchair.com/jc.2018-00229.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAcIwggG-BgkqhkiG9w0BBwagggGvMIIBqwIBADCCAaQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMGSlmWlButqkZOjXCAgEQgIIBdQSZOtdqDb5r6OPayuvZTEPALno41vNVgyJpD-pQvRa9AzuBvZY8A0LYOrFS8dxRlf19GETJcFtXMDd8CYpzhQmiioxBmMoVtZHqgAhDoi8t8XVoP-u0CUQMgP1e6nF7CEP1unVf1lPAJHk7Fa6HoOLrL0DAxD6hV-luRftUNW57665jZgdQsVmwhdr4vep0LcgLkqn-Gvtl30uqJJMBQAdzA-TwqEqQUIIReyhQ0T0X3ELB-z_oFPGbyQr1maUK-csBkM4Ijjy0c7rUgvdnDWEkzn_XlBbb0wsd47YEUFATbj-CA2omltWfF5mgL4FpZw3_3lyIMNek5SgjEkxhSwYD04eDGMCTxJ3aYuPTTCO1dPox9UJ8nbX0nswpVhE3Z8Rg1YO6-ai6yvB_jeP_PA0sJT1mvUykUe7kvhyCe5VcNfqzZHIGNR-dBMHO2XcWC00TY9_D4rXrcOMyHg2csWdQERyHIJsXT7tiZUE_6TK_3RPH7U0"]Click here[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Endocrine Society Releases New Version of their Testosterone Clinical Practice Guideline
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top